Tag: 上海品茶网XVU

STAT+ Conversations: A conversation on drug pricing, policy, and access

first_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. STAT+ Conversations: A conversation on drug pricing, policy, and access By Ed Silverman Dec. 1, 2020 Reprints STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Editor’s note: A recording of this conversation is embedded below. Every week, STAT+ subscribers get access to exclusive conversations with biotech, pharma and health tech leaders. This week, Pharmalot columnist, Ed Silverman, is joined by former executive vice president and chief commercial officer of Gilead Sciences, Jim Meyers. Together they will discuss all things drug pricing, policy, and access, and of course, be taking your questions live. Log In | Learn More [email protected] What is it? Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED @Pharmalot About the Author Reprints Tags drug developmentdrug pricingpharmaceuticals Ed Silverman Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. GET STARTED What’s included? Pharma last_img read more

Read More